Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration

Phase 1 Unknown 39 enrolled Dr Jean Yannis PERENTES

RandomizedSequentialOpen-labelTreatment

Summary

Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).

Timeline

Start: 2023-11-24
Primary completion: 2025-12-01
Completion: 2026-02-01

Publications

Chriqui LE, Abdelnour-Berchtold E, Zanfrini E, Devesa-Perez S, Gonzalez M, Krueger T, Ellefsen K, Destaillats A, Bonnet D, Hubner M, Bouchaab H, Bassani-Sternberg M, Peters S, Cavin S, Perentes JY. Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis. Cancer Treat Res Commun. 2024;42:100858. doi: 10.1016/j.ctarc.2024.100858. Epub 2024 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	7.5 mg/m2	Other
Subject	Cisplatin	Other / unclassified	12.5 mg/m2	Other
Subject	Cisplatin	Other / unclassified	35 mg/m2	Other
Subject	Cisplatin	Other / unclassified	70 mg/m2	Other

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration

Summary

Timeline

Publications

Drugs

Indications